Te­va talks tough on cuts; Take­da bol­sters start­up with a ded­i­cat­ed car­dio dis­cov­ery team

→ With its share price plum­met­ing as the rev­enue num­bers de­te­ri­o­rate at a rapid pace, Is­rael’s trou­bled Te­va talked up deep cuts to­day, with plans for ax­ing thou­sands of jobs as well as a com­plete re­vamp on man­u­fac­tur­ing that in­cludes shut­ter­ing or di­vest­ing nine fa­cil­i­ties.

→ Cam­bridge, MA-based start­up Car­du­ri­on is get­ting start­ed with a cre­ative al­liance with Take­da. The phar­ma com­pa­ny — which has been re­vamp­ing R&D — is pro­vid­ing the lit­tle biotech with a 12-per­son car­dio re­search team in Japan for its dis­cov­ery work, look­ing to kin­dle some R&D mag­ic in the al­liance of a glob­al play­er and a biotech up­start. Car­du­ri­on is run by two in­dus­try vet­er­ans: CEO Daniel Bloom­field and Michael Mendel­sohn, founder and ex­ec­u­tive chair­man. The cre­ation of this part­ner­ship with Car­du­ri­on fol­lows Take­da’s strat­e­gy to lever­age ex­ter­nal in­no­va­tion by plac­ing se­lect­ed as­sets and out­stand­ing sci­en­tists in­to en­tre­pre­neur­ial en­vi­ron­ments,” said An­drew Plump, chief med­ical and sci­en­tif­ic of­fi­cer, Take­da. “By lever­ag­ing the high lev­el of ther­a­peu­tic ex­per­tise at Take­da’s Shonan Re­search Cen­ter to sup­port drug dis­cov­ery, we’re mo­ti­vat­ing sci­en­tists to come to­geth­er to de­liv­er on our promise of serv­ing pa­tients with ex­ist­ing un­met needs.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER